Figure 2.

Cochrane Risk of Bias 2 tool summary for considered trials. ACS, acute coronary syndrome; AFIRE, Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease; AUGUSTUS, Apixaban Versus Warfarin in Patients with AF and ACS or PCI; DOAC, direct oral anticoagulant; DPT, dual-platelet therapy; ENTRUST, Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI); ID, identification; OAC-ALONE, Optimizing Antithrombotic Care in Patients With Atrial Fibrillation and Coronary Stent; PCI, percutaneous coronary intervention; PIONEER, Exploration of Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo a Percutaneous Coronary Intervention (PIONEER-AF PCI); RE-DUAL, Randomized Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (RE-DUAL PCI); VKA, vitamin-K antagonist.